Form 6-K — CureVac N.V.: Phase 1 study of the COVID-19 mRNA vaccine candidate CV0501 (August 18, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission, Commission File Number 001-39446. It states that on August 18, 2022 the company issued a press release announcing the start of a study of the modified COVID-19 mRNA vaccine candidate CV0501, developed in collaboration with GlaxoSmithKline. The report says the candidate is based on the company's second-generation mRNA backbone and is designed to specifically protect against the Omicron variant. The information is incorporated by reference into Form F-3, File No. 333-259613, except for statements of the Chief Development Officer in the exhibit, which is Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: Phase 1 study of the COVID-19 mRNA vaccine candidate CV0501 (August 18, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-08-18-0001104659-22-092556-32e344d34b/
, SHA-256 f626c7d310c6f95aa159b60cf5e337c07e15195a8f57f3afe62a3e70d94681ec.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On August 18, 2022, CureVac N.V. (the “Company”) issued a press release announcing the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, developed in collaboration with GlaxoSmithKline (“GSK”). The vaccine candidate is based on the Company’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Company’s Chief Development Officer contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: August 18, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated August 18, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-08-18_0001104659-22-092556.htm
- Size
- 13,592 bytes
- SHA-256
- f626c7d310c6f95aa159b60cf5e337c07e15195a8f57f3afe62a3e70d94681ec
- Original
- www.sec.gov